|
Oct 16
|
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
|
|
Oct 15
|
Pharvaris to Host Virtual Investor Event on October 23, 2024
|
|
Oct 3
|
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
|
|
May 8
|
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Dec 8
|
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
|
|
Dec 7
|
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
|
|
Dec 7
|
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
|
|
Dec 6
|
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
|
|
Dec 6
|
Pharvaris shares spike as drug appears to prevent symptoms of rare disorder
|
|
Dec 6
|
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
|
|
Nov 30
|
Pharvaris to Present at the GA²LEN UCARE Conference 2023
|
|
Sep 6
|
Pharvaris To Present at the 18th German Allergy Congress
|
|
Sep 6
|
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Jul 21
|
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
|